Thrombotic risk assessment in antiphospholipid syndrome: the role of new antibody specificities and thrombin generation assay

Table 2 The global antiphospholipid syndrome score (GAPSS)

	Factor	Point value^a
aPL^a	Anticardiolipin IgG/IgM	5
	Anti-β2-glycoprotein IgG/IgM	4
	Lupus anticoagulant	4
	Anti-prothrombin/phosphatidylserine complex (aPS/PT) IgG/IgM	3
Cardiovascular risk factors	Hyperlipidemia^b	3
	Arterial hypertension^c	1

Cardiovascular risk factors were assessed following National Institute for Health and Clinical Excellence guidelines (Excellence NIfHaC. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. 2010. URL: http://www.nice.org.uk/guidance/CG181 and Excellence NIfHaC. Hypertension. 2011. URL: http://www.nice.org.uk/guidance/QS28)
^aaPL positivity was assessed according to the updated APS classification criteria [5]
^bSerum total and high-density lipoprotein cholesterol levels were determined with standardized enzymatic methods and interpreted according to current cutoff values (total cholesterol of <5.0 mmol/l; <3.0 mmol/l for low-density lipoprotein cholesterol) (British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005; Suppl 5:v1–52)
^cArterial hypertension was defined as appropriately sized high blood pressure cutoff (140/90 mm Hg or higher) at least in two occasions or use of oral antihypertensive medications

ISSN: 1476-7961